Q-omics provides the consensus-scored RPLP0P2 profile across patient tissues and cancer cell-line models. RPLP0P2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPLP0P2 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, RPLP0P2 RNA expression shows 14,622 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, HNSC, and LUAD as cancer lineages where RPLP0P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPLP0P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPLP0P2 survival associations across molecular data types. RPLP0P2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPLP0P2 RNA expression–survival associations across cancer types. High RPLP0P2 expression shows unfavorable associations in KIRC, KIRP, ACC, MESO, UVM and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPLP0P2 RNA expression.
This table summarizes RPLP0P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPLP0P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPLP0P2 shows lower tumor expression in KIRC and higher tumor expression in HNSC, BLCA, COAD, STAD and THCA. The HNSC box plot shows higher RPLP0P2 RNA expression in tumor versus normal tissue (log2 FC = +2.318, t-test p < 0.001).
This table shows molecular features associated with RPLP0P2 in patient tissues and cancer cell lines. In patient samples, RPLP0P2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
